Cardiol Therapeutics Announces Year-End 2025 Update on Operations

Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026.Reported positive Phase II ARCHER data ...

Mako Mining Corp.: Mako Mining Reports Fourth Quarter and Full Year 2025 Financial Results, Including Q4 2025 Adjusted EBITDA of US$28.3 million and EPS of US$0.17/share from ...

VANCOUVER, BC / ACCESS Newswire / April 1, 2026 / Mako Mining Corp. (TSX-V:MKO)(NASDAQ:MAKO) ("Mako" or the "Company") is pleased to provide financial results for the three months and year ended Decem ...

U.S. Gold Corp. Delivers Robust Feasibility Study For Ck Gold Project Highlighting Attractive Economics And Detailing Relative Low Development Risk

U.S. Gold Corp. ("US Gold" or the "Company") (NASDAQ: USAU) is pleased to announce the results of its Feasibility Study (the "FS") for the development ...